Gamco Investors INC. ET AL increased its position in shares of GRIFOLS S A/S (NASDAQ:GRFS) by 55.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,500 shares of the biotechnology company’s stock after acquiring an additional 16,500 shares during the period. Gamco Investors INC. ET AL’s holdings in GRIFOLS S A/S were worth $1,000,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also recently made changes to their positions in the company. Suntrust Banks Inc. purchased a new stake in shares of GRIFOLS S A/S during the first quarter worth $252,000. First Republic Investment Management Inc. raised its holdings in shares of GRIFOLS S A/S by 35.0% during the first quarter. First Republic Investment Management Inc. now owns 12,892 shares of the biotechnology company’s stock worth $273,000 after acquiring an additional 3,340 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of GRIFOLS S A/S during the first quarter worth $285,000. Financial Gravity Wealth Inc. purchased a new stake in shares of GRIFOLS S A/S during the first quarter worth $282,000. Finally, Commerce Bank purchased a new stake in shares of GRIFOLS S A/S during the first quarter worth $313,000. Institutional investors and hedge funds own 21.07% of the company’s stock.
GRIFOLS S A/S stock opened at $20.50 on Friday. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.12 and a current ratio of 2.90. The firm has a market cap of $14.52 billion, a price-to-earnings ratio of 18.64 and a beta of 1.19. GRIFOLS S A/S has a one year low of $19.94 and a one year high of $25.18.
GRIFOLS S A/S (NASDAQ:GRFS) last posted its earnings results on Friday, July 27th. The biotechnology company reported $0.34 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.34. The firm had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.35 billion. GRIFOLS S A/S had a net margin of 16.55% and a return on equity of 17.78%. sell-side analysts predict that GRIFOLS S A/S will post 1.23 EPS for the current fiscal year.
Several brokerages recently issued reports on GRFS. JPMorgan Chase & Co. lowered GRIFOLS S A/S from an “overweight” rating to a “neutral” rating in a report on Wednesday, June 13th. BidaskClub upgraded GRIFOLS S A/S from a “sell” rating to a “hold” rating in a report on Tuesday, May 15th. Zacks Investment Research upgraded GRIFOLS S A/S from a “sell” rating to a “hold” rating in a report on Friday, June 22nd. Finally, Barclays initiated coverage on shares of GRIFOLS S A/S in a research report on Friday, June 1st. They set an “overweight” rating on the stock. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $22.50.
GRIFOLS S A/S Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.